Repeal of Michigan’s Engler-era drug immunity law passes House - michiganadvance.com
Michigan's House has repealed the Engler-era drug immunity law, impacting liability protections for drug manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers operating in Michigan, including branded and generic drug makers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate action is recommended as the repeal is effective now.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The repeal removes previous immunity protections for drug manufacturers against certain liabilities.
Who it affects
All pharmaceutical manufacturers operating in Michigan, including branded and generic drug makers.
What you must do
Review and adjust liability insurance policies and risk management strategies in light of the repeal.
Deadline
Immediate action is recommended as the repeal is effective now.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- The FDA just cleared the way for drug importation. What now? - politico.com
- EPA names BD, Edwards and Medtronic on list of higher-risk sterilization facilities - MedTech Dive
- COVID-19 vaccines may be harder to get in Kentucky under new FDA guidelines. Here's why - The Courier-Journal
- Greek national indicted for selling counterfeit and unapproved prescription drugs to internet pharmacies and undercover agents - justice.gov
- Pfizer Kansas plant hit by FDA 483 with 8 repeat observations - bioprocessintl.com